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Abstract
Introduction: Regular replacement with immunoglobulin infusions is the mainstay of treatment in the majority of 
primary immunodeficiencies. Several studies showed that Subcutaneous Immunoglobulin (SCIG) has similar efficacy 
to Intravenous Immunoglobulin (IVIG) in preventing infections in PID patients. Here we report effectiveness, safety 
and tolerance of SCIG replacement therapy by push in 32 pediatric and adult patients with humoral PID in Argentina. 
Results: We describe 32 patients that received SCIG treatment between July 2011 and May 2012. 17 male and 
15 female from 2 Immunology Centers; aged from 8 months to 40 years (median: 11 years). 30 patients previously 
received IVIG treatment. Among them, fifteen received 9 months of SCIG treatment administered by pump. The other 
2 patients started the immunoglobulin replacement treatment directly with SCIG by push. The mean dose of SCIG was 
133 mg/kg/week (range 100-192). The annual rate of any infection was 1, 2 infection/year/patient for subcutaneous 
treatment. The frequency of adverse effects was 0.02% with the SCIG. At the end of the study, all patients chose SCIG 
home-therapy regimen and referred much more comfort with SCIG by push. 
Conclusion: Self-administered subcutaneous immunoglobulin therapy by push is an effective and safe alternative 
therapy for patients with PID.
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Introduction
Primary Immunodeficiency Diseases (PID) comprise more than 
200 different congenital disorders that affect the development, function, 
or both of the immune system, leading to increased frequency of 
infections, mainly bacterial infections of the respiratory tract [1-3]. 
Regular replacement with immunoglobulin infusions is the mainstay 
of treatment in the majority of primary immunodeficiencies, both in 
antibody deficiencies and in severe T cells deficiencies [4,5]. 
Subcutaneous Infusions of Immunoglobulin (SCIG) were 
introduced in 1980 in US and since then, they have been increasingly 
used in this country and in Europe [6]. Several studies have shown that 
SCIG has similar efficacy to Intravenous Immunoglobulin (IVIG) in 
preventing infections in PID patients [7-14]. The low risk of systemic 
adverse reactions makes the subcutaneous route for IgG administration 
a good choice for home-therapy and an excellent alternative to patients 
with poor venous access or severe adverse effects with IVIG [7,15,16]. 
Beriglobina P MR (CSL Behring), a preparation of human 
immunoglobulin to be administered subcutaneously, was approved by 
the Argentinian Health Department, Secretaría de Políticas, Regulación 
y Relaciones Sanitarias A.N.M.A.T. in 2010 (www.anmat.gov.ar). Since 
then, we have started using SCIG as replacement therapy and we have 
made a multicentric study with 15 pediatric patients with PID during 
nine months to compare SCIG effectiveness, safety and tolerance, 
administered by pump vs. IVIG [17]. According to the improvement 
of the serum IgG levels reached with SCIG infusions, the reduction 
of infectious episodes and the decrease of moderate and severe 
adverse events with this kind of treatment, we continued prescribing 
replacement therapy with SCIG in more children and adult patients 
with humoral PID but we are still dealing with the difficulties related 
to the pump costs. Shapiro et al. [18] showed the feasibility to use the 
SCIG therapy by push, and for that reason we started administrating 
SCIG by push since July 2011.
Here we report effectiveness, safety and tolerance of SCIG 
replacement therapy by push in 32 pediatric and adult patients with 
humoral PID in Argentine. 
Material and Methods
Study design
This is an observational, descriptive and ambispective study. The 
objective is to describe the effectiveness, safety and tolerance of SCIG 
therapy by push in patients that received this treatment in our center 
between July 2011 and May 2012.
Baseline data, including steady-state serum IgG levels, bacterial 
infections, and adverse reactions, were obtained from the medical 
records.
This protocol was approved by the ethics committee for each 
hospital and written informed consent was obtained.
Patients
To be included in the study, patients must have a Humoral PID 
diagnosis that required immunoglobulin replacement treatment. 
Patients with chronic infections like Hepatitis-B Virus (HBV), 
Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus-1 
(HIV-1) were excluded.
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The diagnosis of Humoral PID was one of the following: X-linked 
Agammaglobulinemia (XLA) (Diagnostic criteria: ESID/PAGID 1999) 
[19], Common Variable Immunodeficiency (CVID) (Diagnostic criteria: 
ESID/PAGID 1999) [19], Hyper IgM Syndrome (SHIM) (Diagnostic 
criteria: IgG<2 SD, absent IgA, IgM>2 SD and normal number of B 
lymphocyte) in one woman, Severe Hipogammaglobulinemia (SH) 
(Diagnostic criteria: Serum IgG<300 mg% and B Lymphocyte>2%) 
or Specific Antibody Deficiency (SAD) (Diagnostic criteria: Patients 
with impaired response to pneumococcal antigens with the 23-valent 
pneumococcal vaccine and normal IgG values per age) [20].
Bronchiectasis was defined as an abnormal and irreversible 
dilatation of the bronchi, frequently associated with inflammation.
The protocol was approved by the independent ethics committee 
for each hospital and written informed consent was obtained for each 
subject or their parents if they were under 18 years old. The study was 
performed in accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines as well as any applicable local regulations.
Treatment: Doses and SCIG infusion technique
We used Beriglobina P (CSL Behring), ready-to-use pasteurized 
preparation of human polyvalent immunoglobulin to be administered 
subcutaneously, at a concentration of 16% (160 mg/ml).
If the patient was receiving IVIG treatment previously, weekly 
dosage of SCIG was calculated by dividing the previous IVIG monthly 
dose by 4, so the patients received in the SCIG therapy the same dose 
as in the IVIG therapy. The administration route was switched 7 days 
after the last intravenous infusion. The patients that had started the 
immunoglobulin treatment with SCIG received weekly infusions of 
SCIG at a dose of 100-150 mg/kg/week.
A period of 4-6 training weeks in hospital before home self-
administration was provided. The family member in charge or the 
own patient learned about the use of premedication, the technique of 
application and instructions to complete the register with details of 
each home infusion, infections and adverse reactions. 
The product was administered at 1 or multiple injection sites, by 
push with rates limited to 1 ml/min and in each site a maximum of 20 
ml in children and 35 ml in adults.
Physical examination and blood assessments
Physical investigations were performed each time the patient visited 
the clinic. Vital signs (blood pressure, heart rate, respiratory rate, and 
body temperature) were recorded before and during infusion at first 4-6 
weeks (training sessions). 
Serum immunoglobulin (IgG, IgA, and IgM) (Method: Kinetic 
Nephelometry-Immunochemistry System IMMAGE, Beckman-
Coulter), hematological status and clinical chemistry profile were 
determined before the infusions at weeks 2, 4, 8, 16, 24 and 36 in all 
patients. Viral tests were done on patient blood samples before starting 
the SCIG treatment and at the end of the study and included Hepatitis-B 
surface antigen, polymerase chain reaction HCV and HIV-1.
Effectiveness 
Effectiveness was measured by IgG levels and the number and 
characteristics of bacterial infections. Serious bacterial infection had 
been defined as meningitis, sepsis, osteomyelitis or visceral abscesses 
according to the definition of the US Food and Drug Administration 
[21].
The immunologist in charge of the patient documented the 
characteristics of infections. 
At the end of study, patients were asked about what kind of IgG 
regimen infusion they preferred to continue with IVIG, SCIG by pump 
or SCIG by push.
Tolerance
Tolerance was evaluated by the number and type of Adverse Events 
(AEs). They were classified in mild (local erythema, swelling, pruritus 
or pain for more than 24 hrs after the infusion), moderate (headache, 
fever, vomiting, urticaria) and severe (cyanosis, meningism or other 
sign of life threatening); local AEs (infusion-site reaction) and systemic 
AEs (treatment related and no infusion-site reaction). 
Statistical analysis
Data was analyzed using descriptive statistics (mean, Standard 
Deviation [SD], median, and minimum and maximum). Frequencies 
and percentages were calculated for the qualitative variables; these were 
compared using the chi-squared independence test. When quantitative 
variables (IgG dosages) were compared in different weeks, a repeated 
measure analysis of variance (ANOVA) was applied. In all cases <5% 
was used to reject the null hypothesis (no difference).
Results
Patients
In the period of study, from July 2011 to May 2012, 32 patients 
from two Immunology Centers started SCIG treatment: 2 X-linked 
Agammaglobulinemia, 12 Common Variable Immunodeficiency, 1 
Hyper IgM Syndrome, 5 Severe Hypogammaglobulinemia and 12 
Specific Antibody Deficiency. 
They were 17 male and 15 female; aged from 8 months to 40 years 
(median 11 years). 13 patients had documented bronchiectasis before 
the beginning of the SCIG treatment (Table 1).
There were 30 patients that had previously received IVIG treatment, 
for at least 48 weeks and all of them presented stable IgG serum levels 
(>500 mg/dl). In this patients IgG serum levels were dosed every 4 
months. Among them, 15 patients had received first IVIG and after 
that 9 months of SCIG treatment administered by pump. The other 2 
patients started the immunoglobulin replace treatment directly with 
SCIG.
For all patients, hematological and clinical chemistry profile results 
were normal and infectious studies were negatives. 
Doses and SCIG infusion technique
The mean dose of SCIG was 133 mg/kg/week (range 100-192). 
Prophylactic antihistamines were prescribed to all patients at the 
Frequency %
Sex
Male 17 53.1%
Female 15 46.9%
Diagnosis
XLA 2 6.2%
SH 5 15.6%
CVID 12 37.5%
SAD 12 37.5%
SHIM 1 3.1%
Bronchiectasis
Yes 13 40.6%
No 19 59.4%
Table 1: Patient demographic and baseline characteristics.
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beginning of the SCIG treatment but at the end of the study only 78% 
(25/32) chose to continue taking this treatment. 
The abdomen was used as injection site in 29/32 patients and the 
thigh was used in 3/32 with good tolerance. 2 infusion sites were used 
18/32 patients, 1 site was used in 13/32, and 3 sites per session were 
used in 1/32 patient.
Effectiveness 
Measurement IgG levels in IVIG and SCIG therapy: In 30 
patients that had previously received IVIG, an increase in IgG plasma 
concentration was observed following the switch from IVIG to SCIG 
administration (Figure 1). The mean serum IgG level during the last 
48 weeks of the IVIG treatment was 1005 (419) mg/dl compared to 
1264 (535) mg/dl at week 24, 1205 (458) mg/dl at week 36 with SCIG 
treatment (Table 2). There was a statistically significant increase in the 
mean IgG level at weeks 24 and 36 compared to the mean IgG level 
during IVIG treatment (p<0.001). 
Infections (number, type and severity): With SCIG treatment, 16 
of the 32 patients (50%) presented 32 ambulatory infection episodes 
during the period of study (48 weeks): otitis media, bronchitis, 
pneumonia. Three patients presented a pneumonia episode that 
required hospital admission. 
Among the group of patients that previously received IVIG, 
during the last 48 weeks with IVIG, 18 patients (60%) had 69 infection 
episodes: otitis media, sinusitis, bronchitis, pneumonias; five patients 
presented an infection that required hospital admission (4 pneumonias, 
1 bronchitis).
The annual rate of all infections (ambulatory plus hospitalized) 
was 2, 7 infections/year/patient for intravenous route compared to 1, 2 
infections/year/patient for subcutaneous treatment.
13/32 patients had bronchiectasis with IVIG treatment, 39 lower 
respiratory infections episodes (27 bronchitis and 12 pneumonias) were 
suffered in five patients with bronchiectasis. With SCIG treatment, 10 
lower respiratory infections episodes (9 bronchitis and 1 pneumonia) 
were diagnosed in two patients with bronchiectasis.
Tolerance (number and type of AEs): During the study period, 
1152 SCIG infusion were administered. 6/32 patients reported 34 events 
of adverse reactions (34/1152 infusions=0.02 adverse effect/infusion). 
Five patients presented 32 mild episodes related with the injection site 
and only one presented 2 moderate adverse reactions (headache). 
Regarding the mild adverse reactions, five patients related 32 
episodes that last for more than 24 hrs: erythema (10 episodes), swelling 
(8 episodes), itching (4 episodes) and local pain (10 episodes). 
Among 30 patients with previous IVIG treatment, in the last 48 
weeks, 270 IVIG infusions had been administered, 10/30 patients 
reported 36 events of adverse reactions (36/270 infusions=0.13 adverse 
effect/infusion). One (3.3%) patient referred 3 episodes of mild adverse 
effects related with the site of infusion (pain). Nine (30%) patients 
reported 32 events of moderated adverse reaction with different IVIG 
products: 7 patients had headache (24 events), 3 patients had fever (4 
events), 3 patients had vomits (4 events), and one patient presented 1 
episode of severe adverse effect: dyspnea, cyanosis and meningism. 
 
 
 
  Mean of SCIG infusions 
(32 patients) 
Mean of last year  
of IVIG infusions  
(30 patients) 
An increase in IgG plasma concentration was observed following the switch 
from IVIG to SCIG administration. Boxes represent 25 and 75 percentile 
values. Error bars represent the 5 and 95 percentile values.
Figure 1: Median IgG plasma concentration before and during SCIG 
replacement therapy. 
Mean Standard deviation
12 months prior to SCIG treatment
(30 patients with IVIG) 1005.33 419.420
SCIG week 24 (32 patients) 1263.60 534.638
SCIG week 36 (32 patients) 1205.47 457.990
Table 2: Serum IgG levels before and during SCIG replacement therapy. Type of adverse event With IVIgG
* treatment 
30 patients
With SCIgG† treatment
32 patients
Episodes in numbers 
(patients affected)
Episodes in numbers 
(patients affected)
Mild 3 (1) 32 (5)
Local Erithema 0 10 (4)
Local Swelling 0 8 (2)
Local Pain 3 (1) 10 (2)
Local Pruritus/Eczema 0 4 (2)
Moderate 32 (8) 2 (1)
Headache 24 (7) 2 (1)
Fever 4 (3) 0
Vomiting 4 (3) 0
Urticaria 0 0
Severe 1 (1) 0
Dyspnea cyanosis 
meningism 1 (1) 0
Total episodes 36 (10) 34 (6)
Total infusions 270 1152
Rate (episodes/
infusion) 0.13 0.02
The reports of adverse effects of each patient have individual variations, considering 
the method of home self register.
*IVIgG: Intravenous Immunoglobuline G.
†SCIgG: Subcutaneous Immunoglobuline.
Table 3: Frequency and type of adverse events.
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At the end of the study we asked the patients which administration 
route they preferred to continue with the treatment and all of them 
chose the SCIG home-therapy regimen, based on weekly self-infusions. 
Among 15 patients that had previously received SCIG treatment 
by pump, all of them preferred to continue the administration by push 
(Table 3).
Discussion
Appropriate treatment with IVIG or SCIG is the most important 
aspect of management for majority of individuals with PID. Different 
authors have reported a number of potential benefits of subcutaneous 
administration of immunoglobulin [11]. This study demonstrated 
the efficacy, safety and tolerability of self-administered subcutaneous 
immunoglobulin therapy by push in pediatric and adult patients with 
PID. 
With the incorporation of therapeutic IVIG in PID in Argentina, 
we have seen a marked improvement in the quality of patient’s life. 
Nowadays the possibility of using SCIG allow us to offer another 
treatment option to our patients. Our study evaluates the evolution 
of 32 pediatric and adult patients with antibody deficiencies which 
received SCIG between July 2011 and May 2012, 30 of which had 
previous received IVIG treatment. 
The efficacy data collected during the study is similar to that 
reported from previous trials using other subcutaneously administered 
immunoglobulin preparations [13,22,23].
According to what we described before in a multicentric study 
with 15 pediatric patients with PID comparing effectiveness, safety 
and tolerance with SCIG administered by pump vs. IVIG in Argentina 
[17], serum IgG levels during SCIG therapy reached therapeutic values. 
When we compared the IgG levels in IVIG and SCIG treatment, we 
observed that the median ratio of serum IgG levels during SCIG therapy 
was higher (p<0.001). The serum IgG levels kept constant during 
the evaluation period, there were no oscillations of serum IgG levels 
between consecutive SCIG infusions according to other publications 
[24-26].
Also, we observed a reduction of infectious events and requirement 
of hospitalization. Considering only 30 patients that had previously 
received IVIG, the number of ambulatory infections was reduced 
during the SCIG treatment in all patients. It is important to highlight 
that the lower respiratory tract infections decreased in patients with 
bronchiectasis. We hypothesize that the decrease in infectious processes 
could be a consequence of the higher serum IgG levels achieved with 
SCIG.
The benefits of SCIG include elimination of venous access, 
improvement and stabilization of serum IgG levels, less number and 
severity of infections and decreased systemic adverse reactions. The 
potential risk of life-threatening anaphylactic shock may be reduced or 
even eliminated. 
Subcutaneous administration was generally well tolerated, with 
no systemic or clinically significant adverse reactions [13,22,23]. 
According to other publications almost every injection-site reaction 
was mild. Although some of the patients experienced treatment-related 
AEs, this was primarily due to infusion-site reactions including local 
erythema, swelling, itching and pain. In the different variables analyzed 
there were no significant differences in sex and age.
Quality-of-life studies have consistently shown that self infusion 
at home is crucial for patient satisfaction [27,28]. At the end of study 
and in order to continue with their treatment, all patients chosed the 
SCIG home-therapy regimen based on, weekly self-infusions among 
the ones that had received SCIG treatment by pump before. All of 
them referred to be more comfortable administering the SCIG by push. 
Most importantly, all participating patients managed, without further 
difficulties, the task of self infusion at home. 
Concluding, the data from this study confirms that self-
administered, subcutaneous immunoglobulin therapy by push is an 
effective and safe alternative therapy for patients with PID. 
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